Trial of APG-2575 for returning or resistant CLL/SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- You have a confirmed diagnosis of CLL or SLL, with measurable swollen areas (like lymph nodes) or an enlarged spleen.
- Your doctor expects you can live at least 12 more weeks.
- Your CLL/SLL is hard to treat: it didn’t respond to, or you couldn’t tolerate, BTK inhibitor treatment and other standard chemo options—or your first BTK treatment didn’t work and chemo isn’t suitable.
- Your daily function is good enough (ECOG score 0 to 2).
- You can sign consent and follow study visits/tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for people with a type of lymphoma called T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help shrink tumors or stop the cancer from growing.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
This trial tests APG-115 alone or with APG-2575 in adults whose T-PLL or NHL has come back or did not respond to treatment. It may help by targeting the cancer cells with a new drug approach when standard therapies have not worked.
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.